Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 6
1994 2
1995 4
1996 5
1997 3
1999 1
2000 1
2001 3
2002 1
2004 1
2005 1
2006 1
2007 3
2008 1
2013 1
2019 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?
Dempke WCM, Zielinski R, Winkler C, Silberman S, Reuther S, Priebe W. Dempke WCM, et al. Eur J Cancer. 2023 May;185:94-104. doi: 10.1016/j.ejca.2023.02.019. Epub 2023 Feb 24. Eur J Cancer. 2023. PMID: 36966697 Free article. Review.
This review will discuss clinically evaluated doxorubicin analogues that were developed as potentially non-cardiotoxic anticancer agents and include recent development of a novel liposomal anthracycline (L-Annamycin) for the treatment of soft-tissue sarcoma metastatic to t …
This review will discuss clinically evaluated doxorubicin analogues that were developed as potentially non-cardiotoxic anticancer agents and …
Phase I study of liposomal annamycin.
Booser DJ, Perez-Soler R, Cossum P, Esparza-Guerra L, Wu QP, Zou Y, Priebe W, Hortobagyi GN. Booser DJ, et al. Cancer Chemother Pharmacol. 2000;46(5):427-32. doi: 10.1007/s002800000177. Cancer Chemother Pharmacol. 2000. PMID: 11127949
Annamycin is a highly lipophilic anthracycline with the ability to bypass the MDR-1 mechanism of cellular drug resistance. In this phase I study, annamycin entrapped in liposomes was administered by a 1- to 2-h intravenous infusion at 3-week intervals. ...
Annamycin is a highly lipophilic anthracycline with the ability to bypass the MDR-1 mechanism of cellular drug resistance. In this ph …
Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer.
Booser DJ, Esteva FJ, Rivera E, Valero V, Esparza-Guerra L, Priebe W, Hortobagyi GN. Booser DJ, et al. Cancer Chemother Pharmacol. 2002 Jul;50(1):6-8. doi: 10.1007/s00280-002-0464-0. Epub 2002 May 21. Cancer Chemother Pharmacol. 2002. PMID: 12111105 Clinical Trial.
Liposomal annamycin (L-AN) has shown antitumor activity in preclinical studies. ...
Liposomal annamycin (L-AN) has shown antitumor activity in preclinical studies. ...
Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia.
Wetzler M, Thomas DA, Wang ES, Shepard R, Ford LA, Heffner TL, Parekh S, Andreeff M, O'Brien S, Kantarjian HM. Wetzler M, et al. Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):430-4. doi: 10.1016/j.clml.2013.03.015. Epub 2013 Jun 10. Clin Lymphoma Myeloma Leuk. 2013. PMID: 23763920 Free PMC article. Clinical Trial.
BACKGROUND: Treatment options for relapsed/refractory ALL in adult patients remain challenging. Annamycin is a highly lipophilic form of the anthracycline doxorubicin with the ability to bypass multidrug resistance mechanisms of cellular drug resistance. PATIENTS AND METHO …
BACKGROUND: Treatment options for relapsed/refractory ALL in adult patients remain challenging. Annamycin is a highly lipophilic form …
Topoisomerase II inhibitors in AML: past, present, and future.
Economides MP, McCue D, Borthakur G, Pemmaraju N. Economides MP, et al. Expert Opin Pharmacother. 2019 Sep;20(13):1637-1644. doi: 10.1080/14656566.2019.1621292. Epub 2019 May 28. Expert Opin Pharmacother. 2019. PMID: 31136213 Review.
Enhanced topoisomerase II targeting by annamycin and related 4-demethoxy anthracycline analogues.
Trevino AV, Woynarowska BA, Herman TS, Priebe W, Woynarowski JM. Trevino AV, et al. Mol Cancer Ther. 2004 Nov;3(11):1403-10. Mol Cancer Ther. 2004. PMID: 15542779
Normal WI-38 fibroblasts, however, were markedly more resistant to annamycin-induced DNA-protein cross-links, apoptosis, and growth inhibition. ...This diversity needs to be recognized as a factor in responses to drugs such as annamycin and doxorubicin....
Normal WI-38 fibroblasts, however, were markedly more resistant to annamycin-induced DNA-protein cross-links, apoptosis, and growth i …
Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells.
Ling YH, Priebe W, Perez-Soler R. Ling YH, et al. Cancer Res. 1993 Apr 15;53(8):1845-52. Cancer Res. 1993. PMID: 8467504
P388 parental cells exposed to various concentrations of doxorubicin and annamycin for 24 h displayed dose-dependent DNA cleavage: at 1 microM, both doxorubicin and annamycin were effective in inducing DNA breakdown, but at 10 microM, the effect was markedly decreas …
P388 parental cells exposed to various concentrations of doxorubicin and annamycin for 24 h displayed dose-dependent DNA cleavage: at …
Blood and plasma lipoprotein distribution and gender differences in the plasma pharmacokinetics of lipid-associated annamycin.
Wasan KM, Kwong M. Wasan KM, et al. Pharmacol Toxicol. 1997 Jun;80(6):301-7. doi: 10.1111/j.1600-0773.1997.tb01978.x. Pharmacol Toxicol. 1997. PMID: 9225368
The objectives of this study were to determine the lipoprotein distribution of unbound annamycin and liposomal annamycin within human and rabbit blood and plasma and to evaluate the plasma pharmacokinetics of liposomal annamycin in male and female rabbits fol …
The objectives of this study were to determine the lipoprotein distribution of unbound annamycin and liposomal annamycin withi …
Effects of liposome-entrapped annamycin in human breast cancer cells: interference with cell cycle progression and induction of apoptosis.
Orlandi L, Bertoli G, Abolafio G, Daidone MG, Zaffaroni N. Orlandi L, et al. J Cell Biochem. 2001;81(1):9-22. doi: 10.1002/1097-4644(20010401)81:1<9::aid-jcb1020>3.0.co;2-c. J Cell Biochem. 2001. PMID: 11180394
The effects of liposome-encapsulated annamycin (L-Ann) were investigated in two human breast cancer cell lines, MCF7 and MDA-MB-435. ...
The effects of liposome-encapsulated annamycin (L-Ann) were investigated in two human breast cancer cell lines, MCF7 and MDA-MB-435. …
Comparison of annamycin to adriamycin in cardiac and MDR tumor cell systems.
Kolonias D, Podona T, Savaraj N, Gate L, Cossum P, Lampidis TJ. Kolonias D, et al. Anticancer Res. 1999 Mar-Apr;19(2A):1277-83. Anticancer Res. 1999. PMID: 10368688
The observation that Adriamycin preferentially accumulates in cardiac-muscle (CM) but not in cardiac non-muscle (NM) cells while Annamycin accumulates equally in both, may explain in part the reduced cardiotoxicity of Annamycin. Moreover, the cytosolic accumulation …
The observation that Adriamycin preferentially accumulates in cardiac-muscle (CM) but not in cardiac non-muscle (NM) cells while Annamyci …
36 results